PAVmed

Update in progress

PAVM (NasdaqCM)

PAVmed Inc. develops, acquires, and commercializes innovative medical devices for unmet needs in the United States. Its portfolio includes CarpX for carpal tunnel release, EsoCheck for detecting early esophageal precancer, EsoGuard a DNA assay using EsoCheck-collected cells, EsoCure for treating dysplastic Barrett’s esophagus, PortIO intraosseous vascular access, and the Veris cancer care platform. Formerly PAXmed, it renamed in 2015. Founded 2014, based in New York.